Halozyme Therapeutics (HALO) Tops Q3 EPS by 6c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $128.95 -1.5%
EPS Growth %: +32.6%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
LTBR, AES, SYRS, More
EPS Growth %: +32.6%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $0.25, $0.06 better than the analyst estimate of $0.19. Revenue for the quarter came in at $65.3 million versus the consensus estimate of $60.9 million.
GUIDANCE:
Halozyme Therapeutics sees FY2020 EPS of $0.80-$0.85, versus the consensus of $0.69. Halozyme Therapeutics sees FY2020 revenue of $250-260 million, versus the consensus of $235.94 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- Ryman Hospitality Properties (RHP) Tops Q3 EPS by 15c
- Parametric Sound (PAMT) Misses Q3 EPS by 31c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
